Use of methylphenidate in the treatment of children with autistic disorder

  • Humberto Quintana
  • Boris Birmaher
  • Deborah Stedge
  • Susan Lennon
  • Jane Freed
  • Jeffrey Bridge
  • Larry Greenhill
Article

Abstract

The use of psychostimulants in autistic disorder has not received extensive evaluation. Furthermore, their use for the symptomatic control of autistic disorder has been felt to be contraindicated. This study investigates the use of methylphenidate (MPH) for the treatment of selected symptoms of autistic disorder. Ten children, ages 7–11, with a DSM-III-R diagnosis of autistic disorder participated in a double-blind crossover study using placebo and two MPH doses (10 mg or 20 mg bid). Subjects showed modest but statistically significant improvement on MPH over placebo. No significant side effects including worsening stereotypic movements occurred on either dose. Improvement in hyperactivity and lack of adverse effects suggest that MPH may be useful in the treatment of hyperactive autistic children.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aman, M. (1988). The use of methylphenidate in autism [Letter to the editor].Journal of the American Academy of Child and Adolescent Psychiatry, 27, 821–822.PubMedGoogle Scholar
  2. Aman, M., & Singh, N. N. (1985). The Aberrant Behavior Checklist.Psychopharmacological Bulletin, 21, 845–850.Google Scholar
  3. American Psychiatric Association. (1968).Diagnostic and statistical manual of mental disorders (2nd ed.). Washington, DC: Author.Google Scholar
  4. American Psychiatric Association. (1980).Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author.Google Scholar
  5. American Psychiatric Association (1987).Diagnostic and statistical manual of mental disorders (3rd ed., rev). Washington, DC: author.Google Scholar
  6. Anderson, L., Campbell, M., Grega, D., et al. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms.American Journal of Psychiatry, 141, 1195–1202.PubMedGoogle Scholar
  7. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Small, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.Journal of Autism and Developmental Disorders, 19, 227–239.PubMedGoogle Scholar
  8. Barkley, R. A., DuPaul, G. J., & McMurray, M. B. (1991). Attention deficit disorder with and without hyperactivity: Clinical response to 3 dose levels of methylphenidate.Pediatrics, 87, 519–531.PubMedGoogle Scholar
  9. Birmaher, B., Quintana, H., & Greenhill, L. (1988). Methylphenidate treatment of hyperactive autistic children.Journal of the American Academy of Child and Adolescent Psychiatry, 27, 248–251.PubMedGoogle Scholar
  10. Campbell, M., Adams, P., Perry, R., Spencer, E. K., & Overall, J. E. (1988). Tardive and withdrawal dyskinesia in autistic children: A prospective study.Psychopharmacology Bulletin, 24, 251–255.PubMedGoogle Scholar
  11. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., & Green, W. H. (1978). A comparison of haloperidol, behavior therapy, and their interactions in autistic children.Journal of the American Academy of Child Psychiatry, 17, 640–655.PubMedGoogle Scholar
  12. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral Symptoms and Attentional Learning.Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.PubMedGoogle Scholar
  13. Campbell, M., Anderson, L., Small, A., et al. (1990). Naltrexone in autistic children: A double-blind and placebo controlled study.Psychopharmacological Bulletin, 26, 130–135.Google Scholar
  14. Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koch, C. (1972). Response to triiodothyronine and dextroamphetamine: A study of preschool, schizophrenic children.Journal of Autism and Childhood Schizophrenia, 2, 343–358.PubMedGoogle Scholar
  15. Campbell, M., Geller, B., & Cohen, I. L. (1977). Current status of drug research and treatment in autistic children.Journal of Pediatric Psychology, 2, 153–161.Google Scholar
  16. Campbell, M., Gonzalez, N. M., Ernst, M., et al. (1993). Neuroleptics. In J. S. Werry & M. G. Aman (Eds.),Practitioners guide to psychoactive drugs for children and adolescents (pp. 269–296). New York: Plenum Press.Google Scholar
  17. Campbell, M., & Green, W. H. (1985). Pervasive developmental disorders of childhood. In H. I. Kaplan & B. J. Sadock (Eds.),Comprehensive textbook of psychiatry (Vol. 4, 4th ed., pp. 1672–1683).Google Scholar
  18. Conners, C. K. (1973). Rating scales for use in drug studies with children. [Special issue]Psychopharmacological Bulletin, 9, 24–42.Google Scholar
  19. Gelfand, R. (1980). Glossary. In H. I. Kaplan, A. M. Freedman, & B. Sadock (Eds.),Comprehensive textbook of psychiatry (Vol. 3, 3rd ed., p. 3334). Baltimore: Williams & Wilkins.Google Scholar
  20. Geller, B., Guttmacher, L., & Bleeg, M. (1981). Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity.American Journal of Psychiatry, 138, 388–389.PubMedGoogle Scholar
  21. Gordon, C. T., State, R. C., Nelson, J. E. et al. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.Archives of General Psychiatry, 50, 441–447.PubMedGoogle Scholar
  22. Goyette, C., Conners, C. K., & Sulrick, R. F. (1978). Normative data on revised Conners parent and teacher ratings scales.Journal of Abnormal Child Psychology, 6, 221–230.PubMedGoogle Scholar
  23. Gualtieri, C. T., Barnhill, J., McGinsey, J., et al. (1980). Tardive dyskinesia and other movement disorders in children treated with psychotropic drugs.Journal of the American Academy of Child Psychiatry, 19, 491–510.PubMedGoogle Scholar
  24. Gualtieri, C. T., Quade, D., Hicks, R. D., et al. (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.American Journal of Psychiatry, 141, 20–23.PubMedGoogle Scholar
  25. Guy, W. (1976).ECDEU assessment manual of psychopharmacology. Rockville, MD: NIMH Psychopharmacology Research Branch.Google Scholar
  26. Hoshino, Y., Kumashiro, H., Kanero, M., & Takahashi, Y. (1977). The effects of methylphenidate in early infantile autism and its relation to serum serotonin levels.Folia Psyciatrica et Neurologica Japonica, 31, 605–614.Google Scholar
  27. Keepers, G. A., Clappison, V. J., & Casey, D. E. (1983). Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.Archives of General Psychiatry, 40, 1113–1117.PubMedGoogle Scholar
  28. McDougle, C. L., Price, L. H., Volkmar, F. R. et al. (1992). Clomipramine in autism: Preliminary evidence of efficacy.Journal of Academy of Child and Adolescent Psychiatry, 31, 746–750.Google Scholar
  29. Perry, R., Campbell, M., Adams, P., et al. (1989). A multidimensional long term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration.Journal of American Academy of Child and Adolescent Psychiatry, 28, 87–92.Google Scholar
  30. Perry, R., Campbell, M., Green, W., Small, A., & Trill, M. (1985). Neuroleptic related dyskinesias in autistic children: A prospective study.Psychopharmacology Bulletin, 21, 140–143.PubMedGoogle Scholar
  31. Schopler, E., Reichler, R. J., & Renner, B. (1985). Childhood Autism Rating Scale (CARS).Psychopharmacology Bulletin, 21, 1052–1053.Google Scholar
  32. Schopler, E., Reichler, R. J., & Renner, B. (1988).Childhood Autism Rating Scale (CARS). Los Angeles: Western Psychological Services.Google Scholar
  33. Sloman, L. (1991). Use of medications in pervasive developmental disorders.Psychiatric Clinics of North America, 14, 165–182.PubMedGoogle Scholar
  34. Strayhorn, J. M., Rapp, N., Donina, W., & Strain, P. S. (1988). Randomized trial of methylphenidate for an autistic child.Journal of the American Academy of Child and Adolescent Psychiatry, 27, 244–247.PubMedGoogle Scholar
  35. Vitriol, C., & Farber, B. (1981). Stimulant medication in certain childhood disorders.American Journal of Psychiatry, 138, 1517–1518.Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Humberto Quintana
    • 1
  • Boris Birmaher
    • 1
  • Deborah Stedge
    • 2
  • Susan Lennon
    • 2
  • Jane Freed
    • 2
  • Jeffrey Bridge
    • 1
  • Larry Greenhill
    • 2
  1. 1.Western Psychiatric Institute and ClinicPittsburgh
  2. 2.New York State Psychiatric InstituteUSA

Personalised recommendations